Crohn's Disease and Colitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with Crohn's disease for more than 6 months, with confirmation from tissue testing recorded in their medical file
- People whose treating doctor has determined that an MRI scan of the bowel (called MRE) is needed as part of their normal care
- People currently on any type of Crohn's disease treatment, including biologics (such as infliximab, adalimumab, vedolizumab, or ustekinumab) or immunosuppressant medications (such as azathioprine, 6-mercaptopurine, or methotrexate)
- People who have signed and dated a written consent form before the study begins
- People who fit into a participant category that the trial still has space for (the trial site will assess this)
Who may not be able to join:
- People who are pregnant during the study
- People who are unable to give consent due to their physical or mental condition
- People who have not provided written consent
- People diagnosed with ulcerative colitis or a type of inflammatory bowel disease that has not been clearly classified
- People who have had certain bowel surgeries, such as an ileoanal anastomosis, ileostomy, or colostomy
- People with fewer than 3 assessable bowel segments, or more than 3 surgically removed bowel segments (not counting the ileocecal valve) (confirm with trial site)
- People with severe symptoms of bowel blockage
- People with an active, symptomatic abscess inside the abdomen
- People for whom an MRI scan is not medically safe
- People whose Crohn's disease affects only the area around the anus, with no involvement of the digestive tract itself
- People whose MRI bowel scan images are of insufficient quality based on the trial's defined standards
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sophie GEYL, CHU Limoge Dupuytren
Phone: +33 5 55 05 66 31
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective definition of depth or grade of transmural healing in relation to radiologic signs observed during Magnetic Resonance Enterography (MRE) in CD
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.